Log In
Print
BCIQ
Print
Print this Print this
 

SIRPalphaFc (formerly TTI-621)

  Manage Alerts
Collapse Summary General Information
Company Trillium Therapeutics Inc.
DescriptionSignal regulatory protein alpha (SIRPA) fused to immunoglobulin Fc region
Molecular Target CD47
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today